drugset
drugset / Trial / NCT02284854

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

NCT02284854 ↗

Phase 1 Completed 43 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ pharmacokinetics.

Timeline

Start
2009-07
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 400 mg —
Subject Eslicarbazepine acetate Unknown 800 mg —

Indications

epilepsy